Paid Clinical Trials and Focus Groups by Category |
|
|
|
Condition: Spinal Cord Injury
Interventions: Device: ReJoyce Workstation; Other: Standard Care
Sponsors: University of Melbourne; Victorian Neurotrauma Initiative; Life Time Care and Support Authority (NSW); University of Western Australia
Recruiting - verified March 2010
Condition: Hypertension
Interventions: Drug: Perindopril; Drug: Perindopril/amlodipine; Drug: Olmesartan/amlodipine
Sponsors: Monash University; Schering-Plough
Not yet recruiting - verified March 2010
Condition: HIV Prevention
Intervention: Drug: Raltegravir
Sponsors: St Vincent's Hospital, Sydney; Merck
Not yet recruiting - verified March 2010
Conditions: Chronic Medical Conditions; Personal Health Records; Electronic Medical Record
Interventions: Device: Electronic (USB) Portable Health File; Device: Paper Portable Health File
Sponsors: St George Hospital, Australia; South Eastern Area Health Service; The University of New South Wales; National Health and Medical Research Council, Australia
Not yet recruiting - verified March 2009
Condition: Cardiovascular Disease
Interventions: Drug: Active Clonidine; Drug: Placebo Clonidine; Drug: Active ASA; Drug: Placebo ASA
Sponsor: Hamilton Health Sciences
Not yet recruiting - verified March 2010
Conditions: Breast Cancer; CYP2D6 Polymorphism
Intervention: Drug: Tamoxifen
Sponsor: Sydney West Area Health Service
Not yet recruiting - verified February 2010
Condition: Hepatocellular Cancer
Intervention:
Sponsor: Sydney West Area Health Service
Recruiting - verified February 2010
Conditions: Metabolic Syndrome; Hypercholesterolemia
Intervention: Drug: Metformin
Sponsor: Sydney West Area Health Service
Recruiting - verified February 2010
Condition: Intubation, Gastrointestinal
Interventions: Drug: Lignocaine; Drug: Placebo
Sponsor: Queensland Children's Medical Research Institute
Not yet recruiting - verified February 2010
Condition: Cardiovascular Diseases
Interventions: Drug: polypill; Drug: Usual cardiovascular medications
Sponsors: Imperial College London; European Commission; Imperial College Healthcare NHS Trust; Royal College of Surgeons, Ireland; UMC Utrecht; The George Institute for International Health India; Public Health Foundation of India; The George Institute; Dr. Reddy's Laboratories Limited
Not yet recruiting - verified March 2010
Condition: Heart Failure
Intervention:
Sponsors: Monash University; The Alfred
Recruiting - verified December 2009
Conditions: Atrial Fibrillation; Arrhythmia; Stroke Prevention; Mortality
Interventions: Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy
Sponsors: Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); Duke University; St. Jude Medical; Biosense Webster, Inc.
Recruiting - verified February 2010
Condition: Malignant Melanoma
Interventions: Drug: ABI-007; Drug: Dacarbazine
Sponsors: Abraxis BioScience Inc.; University of Arizona
Recruiting - verified August 2009
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer; Duke University
Recruiting - verified October 2009
Conditions: Liver Fibrosis; Heart Failure
Intervention: Device: FibroScan
Sponsors: Monash University; The Alfred
Recruiting - verified March 2010
Condition: Huntington's Disease
Interventions: Drug: Creatine Monohydrate (HD-02); Drug: placebo
Sponsors: Massachusetts General Hospital; University of Rochester; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified March 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: Clopidogrel; Drug: Prasugrel; Drug: Commercially-available Aspirin
Sponsors: Eli Lilly and Company; Daiichi Sankyo Co., Ltd.; Duke University
Recruiting - verified March 2010
Condition: Sarcoma
Intervention: Drug: RG1507
Sponsors: Hoffmann-La Roche; Sarcoma Alliance for Research through Collaboration
Active, not recruiting - verified February 2010
Condition: Head and Neck Cancer
Interventions: Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified December 2008
Condition: Cervical Cancer
Interventions: Procedure: Total Abdominal Radical Hysterectomy; Procedure: Total Laparoscopic or Robotic Radical Hysterectomy
Sponsors: Queensland Centre for Gynaecological Cancer; M.D. Anderson Cancer Center
Recruiting - verified February 2010
Condition: Heart Failure
Interventions: Drug: Spironolactone; Drug: Placebo
Sponsors: Monash University; National Heart Foundation, Australia
Recruiting - verified March 2010
Conditions: Atherosclerosis; Myocardial Ischemia; Myocardial Infarction
Interventions: Drug: SCH 530348; Drug: Placebo
Sponsors: Schering-Plough; Duke University
Recruiting - verified March 2010
Condition: Cardiovascular Disease
Intervention:
Sponsor: Monash University
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy; Procedure: videothoracoscopy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified March 2010
Condition: Pelvic Organ Prolapse
Intervention: Procedure: Pelvic Floor Muscle Training
Sponsors: Glasgow Caledonian University; Chief Scientist Office of the Scottish Government; South Glasgow University Hospitals NHS Trust; University of Aberdeen; University of Otago
Active, not recruiting - verified February 2010
Condition: Coronary Artery Disease
Intervention:
Sponsors: Monash University; Royal Brompton & Harefield NHS Foundation Trust; IM Medical Ltd, Melbourne
Recruiting - verified March 2010
Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; The Cleveland Clinic
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Procedure: 7800 cGy/39 fractions in 8 weeks; Procedure: 6000 cGy/20 fractions in 4 weeks
Sponsors: Ontario Clinical Oncology Group (OCOG); Canadian Institutes of Health Research (CIHR); Trans-Tasman Radiation Oncology Group (TROG)
Recruiting - verified February 2010
Condition: Skin Cancer
Interventions: Drug: Carboplatin; Radiation: Radiotherapy
Sponsors: Trans-Tasman Radiation Oncology Group (TROG); Princess Alexandra Hospital, Brisbane, Australia; The Royal Australian and New Zealand College of Radiologists; The Princess Alexandra Hospital Cancer Collaborative Group
Recruiting - verified September 2009
Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified March 2010
Conditions: Stroke; Transient Ischemic Attack
Interventions: Other: folic acid; Dietary Supplement: Vitamin B6; Dietary Supplement: Vitamin B12
Sponsors: VITATOPS; National Health and Medical Research Council, Australia; National Heart Foundation, Australia; Medical Health Research Infrastructure Council, Australia
Completed - verified February 2010
Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate; Drug: triptorelin; Procedure: oophorectomy; Radiation: radiation therapy
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group; National Surgical Adjuvant Breast and Bowel Project (NSABP); Southwest Oncology Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Biological: pegfilgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine; Drug: vincristine sulfate
Sponsors: European Organization for Research and Treatment of Cancer; Lymphoma Trials Office; Groupe d'Etudes de Lymphomes de L'Adulte; Grup per l'Estudi dels Limfomes de Catalunya i Balears; NCIC Clinical Trials Group; Australasian Leukaemia and Lymphoma Group (ALLG); Nordic Lymphoma Group
Active, not recruiting - verified June 2009
Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified March 2010
All Categories ... University Studies » ... Australia 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
